Columbia University

Levo Therapeutics, Inc.

Rudolph L Leibel

Sara Cotter

Wendy K Chung

Dieter Egli

Lisa Cole Burnett

Kazuhisa Watanabe

Elizabeth Watson

Maria Laura Cremona

Loan K Phan

Stuart G Fischer

Charles Leduc

The present invention relates to methods for regulating prohormone convertase (PC1) and compounds and treatments which increase PC1 levels, for treating Prader-Willi Syndrome (PWS).

Methods of treating Prader-Willi syndrome

The invention provides methods for treating metabolic disease in a subject and methods for increasing the expression of ILDR2 in a subject. The invention further provides a method for identifying an agent which modulates expression of an Ildr2 RNA comprising contacting a cell with an agent; determining expression of the Ildr2 RNA in the presence and the absence of the agent; and comparing expression of the Ildr2 RNA in the presence and the absence of the agent, wherein a change in the expression of the Ildr2 RNA in the presence of the agent is indicative of an agent which modulates the level of expression of the RNA.

Methods of treating metabolic disease

This invention provides an isolated mahoganoid polypeptide. This invention also provides an isolated mahoganoid nucleic acid, as well as related nucleic acids, pharmaceutical compositions, antibodies, assay methods, therapeutic methods and articles of manufacture.

Mahoganoid polypeptides, and related compositions and methods

Growing community of inventors

New York, NY, United States of America

Rudolph L Leibel